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This retrospective study aimed to investigate the clinical features associated with deterio-
rated swallow in amyotrophic lateral sclerosis (ALS) patients with spinal and bulbar onset, 
describe the modification of diet and liquid intake, and assess the impact of dysphagia 
on the use of riluzole. One hundred forty-five patients were observed periodically every 
3–6 months. They underwent routinely fiberoptic endoscopic evaluation of swallowing 
(FEES) and spirometry; dysphagia severity was classified according to the Penetration 
Aspiration Scale and the Pooling score (P-score) integrated with other parameters such 
as sensation, collaboration, and age (P-SCA score). During a mean follow-up period of 
about 2 years, the percentage of ALS patients suffering from dysphagia increased to 85 
(rising from 35 to 73% in patients with spinal onset and from 95 to 98% in those with 
bulbar onset). Also, 8% of patients with dysphagia by FEES did not perceive the disorder. 
The frequency of normal and semi-solid diets decreased over time, while that of pureed 
diets and percutaneous endoscopic gastrostomy (PEG) prescription increased. Forty-
four percent of dysphagic patients refused thickeners or PEG. A significant difference 
was observed in the mortality rate between patients untreated with riluzole and patients 
treated with riluzole oral suspension (p < 0.05). Disease duration mainly impacted on the 
frequency of dysphagia in spinal onset patients, appearing very early in those with bulbar 
onset. Riluzole oral suspension would allow the safe administration in dysphagic ALS 
patients to avoid tablet crushing and consequent dispersion in food, common practices 
that are inconsistent with the safe and effective use of the drug.
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inTrODUcTiOn
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a progressive 
loss of motor neurons that leads to paralysis and death within 2–5 years from the time of diagnosis 
(1). Generally, death occurs because of respiratory failure, aspiration pneumonia, malnutrition, and 
dehydration (2).
About one-third of ALS patients show a bulbar onset with dysphagia and dysarthria. Yet, inde-
pendent of the clinical onset, dysphagia emerges in more than 80% of patients during the advanced 
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phases of the disease (3). In ALS, dysphagia is related to tongue 
atrophy, dysfunction in the closure of the soft palate and of the 
larynx due to the nuclear or supranuclear lesion of the cranial 
nerves, IX, X, and XII, and diaphragm dysfunction (4). A prompt 
assessment of the swallowing function is crucial to organize 
proper interventions and prevent rapid clinical deterioration (5). 
Irrespective of the poor prognosis of ALS, adequate adjustment 
of the diet and adoption of postural compensation maneuvers to 
preserve oral feeding could postpone the need for percutaneous 
endoscopic gastrostomy (PEG) (6, 7). Fiberoptic endoscopic 
evaluation of swallowing (FEES) and videofluoroscopic swal-
lowing study are both considered the gold standard to evaluate 
dysphagia (8). However, the endoscopic assessment allows a 
direct examination of the laryngeal adductor reflex (LAR) and 
can be repeated as often as necessary due to absence of radiation 
exposure.
Several methods have been suggested for the treatment of 
oropharyngeal dysphagia in adults to prevent airway aspiration 
during feeding (9, 10). The guidelines for the management of ALS 
recommend PEG when the weight loss exceeds 10% of the base-
line value and the forced vital capacity (FVC) decreases below 
50% of the predicted level (11).
Physiological swallowing is a crucial parameter also for the 
proper intake of drugs, and dysphagia can seriously compromise 
their effect. To date, only riluzole has been approved for the 
treatment of ALS, even if its clinical usefulness remains contro-
versial (12). Moreover, since 2015, a new oral liquid formulation 
of riluzole has become available in Italy (Teglutik, Italfarmaco 
S.p.A.) (13).
Actually, there are no data describing the behavior adopted 
by the patients because of dysphagia, the impact of swallowing 
management programs in prolonging survival and in delaying the 
use of tracheostomy and mechanical ventilation, and the use of 
riluzole in dysphagic ALS patients.
The primary aim of the present study was to describe the 
different clinical features associated with dysphagia in ALS 
patients with spinal and bulbar onset. Furthermore, we aimed to 
investigate the impact of dysphagia on diet and riluzole intake, 
analyze the risk of dysphagia in patients unable to recognize 
disease symptoms, and evaluate the effect of riluzole taken in an 
uncommon way on survival.
MaTerials anD MeThODs
study Design and Patients
Since 2005, an ALS registry has been set up at the Rare 
Neuromuscular Diseases Center of Umberto I Hospital, 
University of Rome “Sapienza.” All consecutive patients with 
a probable or confirmed ALS diagnosis were included in the 
registry. Diagnosis of ALS was based on the El Escorial revised 
criteria (14, 15). According to the most recent guidelines, patients 
underwent visits every 3–6  months, receiving regular support 
from a multidisciplinary care team (16).
In December 2015, we retrospectively conducted an audit 
of the registry to collect dysphagia data in ALS patients who 
underwent visits every 3–6 months to analyze dysphagia onset 
and severity, patient disability, diet modification, and riluzole 
management. Patients were included in this retrospective study 
if they had at least three clinical evaluations comprehensive 
of swallowing assessment (FEES and LAR study) at each visit. 
Patients with concomitant disorders able to induce dysphagia 
were excluded.
Participants were divided into two subgroups, bulbar and 
spinal ALS, according to the clinical onset of disease. These were 
further classified into dysphagic/non-dysphagic and treated/
untreated with riluzole. We defined patients as having a “poor 
prognosis” when death or survival with tracheostomy occurred 
during the observational period.
This study was performed according to the Declaration of 
Helsinki. The authorization to the processing of personal data 
carried out for scientific research purposes or the written consent 
for alive patients was provided by all participants.
clinical assessments
At each visit, the following assessments were performed: (i) 
FEES to evaluate the swallowing function plus completion of the 
Penetration Aspiration Scale (PAS) and Pooling score (P-score); 
(ii) spirometry to test the respiratory function; and (iii) ALS 
Functional Rating Scale Revised (ALSFRS-R) to evaluate the 
functional impairment in ALS.
Fiberoptic endoscopic evaluation of swallowing and LAR, 
performed by an experienced phoniatrician according to the 
Langmore protocol (1999), evaluate objectively the swallowing 
function. A 3.7-mm-diameter flexible fiber-optic rhinolaryn-
goscope (Storz 11101) was used. The endoscopic evaluation 
was performed by checking details of pharyngeal and laryngeal 
surfaces, the competence of the velopharyngeal closure, the mor-
phology, motility, and sensitivity of the larynx, LAR, and secre-
tion residues. The swallowing test consisted in the administration 
of increasing volumes (i.e., 5, 10, and 20 ml) of puree consistency 
(351–1,750 mPa s) and liquids.
Penetration Aspiration Scale grades the severity of swallowing 
dysfunction according to aspiration events (17). It is an 8-point 
scale quantifying penetration and aspiration in order to clarify 
the depth of airway invasion. ALS patients were considered dys-
phagic when the score was >1.
The P-score assesses the ability to control residue/bolus pool-
ing (18). It takes into account (i) site, as identified by anatomical 
landmarks; (ii) amount, as determined in a semiquantitative 
fashion by the amount of pooling materials; (iii) management, 
i.e., the ability of the patient to clear the residue (cough, clear-
ing, gurgling, dry swallow). The P-score may be integrated 
with other parameters of clinical assessment: sensation of the 
pharynx, patient collaboration, and age (P-SCA score) (19) 
(Table 1). Both scores express, as a numerical value, a continuum 
of severity that may indicate the absence of signs of dysphagia, 
mild, moderate, and severe dysphagia (3–4 = minimum score, 
corresponding to no dysphagia; 5–8 = low score, mild dysphagia; 
9–12 = middle score, moderate dysphagia; 13–16 = high score, 
severe dysphagia).
The ALSFRS-R is a validated measure of functional impair-
ment in ALS (20). It is a questionnaire-based functional scale, 
containing 12 items rated from 0 (complete dependence for 
TaBle 1 | The Pooling score (P-score) integrated with parameters as sensation, collaboration, and age (P-sca score) [by Farneti et al. (8)].
Pooling endoscopic landmarks score Bedside parameters
sensation collaboration age (years)
Site Vallecula 1
Marginal zone 1
Pyriform sinus 2
Vestibule/vocal cords 3
Lower vocal cords 4 Presence = −1 Presence = −1 1 (<65)
Absence = 1 Absence = 1 2 (65–75)
Coating 1 3 (>75)
Amount Minimum 2
Maximum 3
Management <2 2
2–5 3
>5 4
Score P: 4–11 P-SCA: 3–16
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that function) to 4 (normal function), divided into 3 sub scores 
(bulbar 12, spinal 24, and respiratory 12), with normal function 
defined by a score of 48.
Spirometry was carried out with participants in the sitting 
position wearing a nose clip, asked to blow into the mouthpiece 
of a spirometer (Winspiro PRO 5.8) as forcefully and quickly as 
possible and to continue blowing until all of the air was expelled 
from lungs. FVC (liters) and forced expiratory volume in first 
second (liters per  second) were analyzed. The highest values 
were used in the analysis. The FVC values were expressed as 
percentages.
The onset of dysphagic symptoms was reported by patients. 
The ability to swallow solid food and liquids was assessed by 
means of anamnestic and clinical criteria. All dietary advice, 
prescription of PEG, non-invasive ventilation (NIV), changes 
in pharmacological treatments, use of thickening agents, and 
adopted diet were collected. Specifically, the patient diet was cat-
egorized as described hereinafter: a normal diet without restric-
tions, a soft diet (>1012 Pa s), a pudding diet (1,750–4,000 mPa s), 
and a pureed diet (351).
The intake of liquid was defined as follows: normal, postural 
(tucked chin), density 1 (syrup-nectar, 51–350 mPa s; it can be 
drunk with a straw or a cup, leaves a thin veneer on the back of 
the spoon), and density 2 (cream, 351–1,750 mPa s; it cannot be 
drunk with a straw; it can be drunk from a cup; it leaves a thin 
veneer on the back of the spoon).
The ability to swallow the whole riluzole tablet has been col-
lected within the description of riluzole modification (crushing/
swallow with food) in case of inability to swallow.
Patient survival has been calculated from the time of diagnosis 
until the date of death.
statistical analysis
Descriptive statistics, which summarizes data as percentages, 
was used. The Student’s T distribution was used to evaluate the 
baseline differences between dysphagic/non-dysphagic patients. 
The Chi-square test, with Yates’ correction if necessary, was used 
to compare qualitative values. Analysis of variance (ANOVA) for 
repeated measures assessed the differences, which were presented 
as percentage and 95% confidence interval. Statistically signifi-
cant ANOVA was confirmed by post hoc Fisher analysis. Overall 
survival was analyzed using the Kaplan–Meier method, and 
P values were calculated using the log-rank test and Wilcoxon 
test. The level of significance was set at 0.05. The data of three 
assessments (i.e., initial, intermediate, and final visit) were used to 
measure disease evolution. The survival analysis was performed 
using Cox Regression.
Generalized linear mixed logit regression models were used to 
examine the association between death and other variables (age at 
onset, type of ALS, PAS, and P-SCA scores).
resUlTs
One hundred and forty five ALS patients (90 males and 55 
females) met the inclusion criteria. They were followed for at 
least 9  months from baseline (mean duration of the clinical 
follow-up was 20.0 ± 18.3 months; range: 9–110). Mean age at 
onset was 62.2 ±  11.7  years. The disease duration at the first 
visit was 15.8 ± 12.7 months (range: 1–78). Fifty-seven patients 
(39%) had bulbar onset, while 88 patients (61%) had a spinal 
onset (Table 2).
At the beginning and at the end of the follow-up period, 
dysphagia was present in 58.6% (85/145) and 82.8% (120/145) 
of patients, respectively, with higher frequency in bulbar than 
in spinal patients (Figure  1). A delayed diagnosis of 14.2 and 
18 months was found in dysphagic and non-dysphagic patients, 
respectively. Abnormal LAR and lower final FVC (F =  53.23, 
η2 = 0.27, p = 0.001) were more frequent among patients with 
bulbar onset. As expected in a progressive disease, a gradual 
significant worsening in PAS score during the follow-up period 
was observed (Figure 2). Six patients (8%) with dysphagia found 
by FEES did not perceive the disorder (Figure 3).
Fifty-four patients died (35% bulbar, 65% spinal) dur-
ing the follow-up, while nine patients survived positioning 
FigUre 1 | incidence of dysphagia in the whole amyotrophic lateral sclerosis population and according to spinal or bulbar onset at the beginning 
and the end of follow-up.
TaBle 2 | Demographic and clinical characteristics of amyotrophic lateral sclerosis (als) patients with or without dysphagia at the start and at the end 
of follow-up.
Variable at the start of follow-up at the end of follow-up
Dysphagic pts non-dysphagic pts p Dysphagic pts non-dysphagic pts p
ALS patients N (%) 85 (58.6) 60 (41.4) 120 (82.8) 25 (17.2)
Clinical onset N (%)
Bulbar 54 (63.5) 3 (5.0) 0.001 56 (46.7) 1 (4.0) 0.001
Spinal 31 (36.5) 57 (95.0) 64 (53.3) 24 (96.0)
Age (years) at onset mean (SD) 64.0 (12.3) 59.6 0.02 63.2 (11.9) 57.4 (9.2) 0.02
Sex N (%)
Male 45 (52.9) 45 (75.0) 0.007 75 (62.5) 15 (60.0) ns
Female 40 (47.1) 15 (25.0) 45 (37.5) 10 (40.0)
Delay of ALS diagnosis (months) mean (SD) 14.2 (10.7) 18.0 (14.8) ns 36.1 (23.5) 35.6 (22.0) ns
Penetration Aspiration Scale mean (SD) 2.4 (1.5) 1.0 (−) 0.001 4.0 (2.0) 1.0 (0.2) 0.001
P-SCA score mean (SD) 6.9 (1.8) 3.1 (0.2) 0.001 9.6 (3.0) 3.4 (0.8) 0.001
ALS Functional Rating Scale Revised mean (SD)
Total 38.3 (7.5) 42.0 (5.4) 0.001 27.1 (8.8) 36.6 (8.4) 0.001
Bulbar 8.6 (2.6) 11.6 (0.7) 0.001 6.8 (3.5) 11.4 (1.6) 0.001
Spinal 18.8 (6.4) 18.8 (5.1) ns 10.9 (7.0) 14.4 (6.6) 0.02
Respiratory 11.0 (1.3) 11.6 (0.9) 0.002 9.4 (2.2) 10.9 (2.2) 0.002
Forced vital capacity mean (SD) 63.8 (21.9) 85.2 (17.9) 0.001 37.3 (31.5) 60.0 (29.4) 0.001
Laryngeal adductor reflex N (%)
Present 52 (61.2) 58 (96.6) 0.001 48 (40.0) 22 (88.0) 0.001
Poor 25 (29.4) 1 (1.7) 30 (25.0) 2 (8.0)
Absent 8 (9.4) 1 (1.7) 42 (35.0) 1 (4.0)
Data are expressed as mean (±SD) or frequencies [N = number (% = percentage value)].
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tracheostomy. At the end of follow-up, disease duration was lower 
in bulbar onset patients than in those with spinal onset.
Sixty-three patients were deemed to have a poor prognosis (54 
patients plus 9 who underwent tracheostomy). They showed a 
significant lower FVC (32.7 + 27.3 vs. 47.7 + 34.2, p = 0.004) in 
comparison to patients who survived. Fifty-five (87%) patients 
were dysphagic, and 25% of them refused the suggested thicken-
ing agents.
Percutaneous endoscopic gastrostomy was applied 
30.6 ±  19.8 months after the onset of symptoms. Also, 29% of 
TaBle 3 | Description of the liquid intake in dysphagic patients (entire 
population and subgrouped by onset).
intake all dysphagic 
patients 
(N = 120)
spinal onset 
dysphagic 
patients 
(N = 64)
Bulbar onset 
dysphagic 
patients 
(N = 56)
p
Normal 8 (7) 7 (11) 1 (2) ns
Postural 31 (26) 20 (31) 11 (20) ns
Syrup/nectar 13 (11) 12 (19) 1(2) 0.007
Cream 43 (36) 22 (34) 21 (37) ns
Percutaneous 
endoscopic 
gastrostomy
25 (20) 3 (5) 22 (39) 0.0001
Data are expressed as frequencies [numbers (%)].
Normal; postural, tuck chin; density 1, syrup (nectar) 51–350 mPa s can be drunk with 
a straw or a cup if recommended; it leaves a thin veneer on the back of the spoon; and 
density 2, cream 351–1,750 mPa s cannot be drunk with a straw; it can be drunk from 
a cup; leaves a thin veneer on the back of the spoon.
FigUre 3 | The fiberoptic endoscopic evaluation of swallowing of one 
amyotrophic lateral sclerosis patient who did not perceive the 
objectified disorder but with abundant hypopharyngeal residues.
FigUre 2 | change in Penetration aspiration scale (Pas) score 
during the follow-up period in spinal and bulbar patients. Current 
effect: F(2.284) = 15.210, p = 0.001. Vertical bars denote 0.95 confidence 
intervals.
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patients with PEG died, showing, however, a longer mean disease 
duration (38.0 ± 21.0 months) when PEG was positioned earlier 
(28.7 ± 22.4 months).
Diet assessment
At the beginning of the observation period 63 patients were on 
a normal diet, 64 on a soft diet, 13 on a pudding diet, and 5 on 
a puree diet. No patient used thickening agents or needed PEG. 
At the end of the follow-up, the following diets were adopted: 
normal in 24 patients, soft in 45 patients, pudding in 35 patients, 
and puree in 11 patients; 30 patients underwent a PEG. Bulbar 
dysphagic patients were given foods with modified consistency 
and underwent PEG more frequently than those with spinal onset 
(p = 0.01).
A detailed description of liquid intake is reported in Table 3. 
Only 56% (30/54) of patients used the suggested thickening 
agents. In particular, 49% of dysphagic patients with spinal onset 
refused the proposed thickeners, while only 15% with bulbar 
onset refused them (p = 0.001 for the difference between bulbar 
and spinal ALS patients). Fifteen patients (62%) who refused the 
proposed thickeners died, while three survived after placing PEG.
Only 75% of patients with poor or absent LAR used thicken-
ers, diets with modified consistence, or PEG. Twelve (63%) of the 
patients who refused the proposed thickeners died.
riluzole Management
At the end of the follow-up period, 95 patients were on riluzole, 
while 50 patients did not take the drug because of excessive 
sedation, increase of levels of transaminases, or patient refusal. 
Among the treated patients, 80 had dysphagia. They took the drug 
as follows: 51 patients used whole tablets (45 with water, 3 with 
fruit juice, 2 with yogurt, and 1 with fruit or bread), 20 crushed 
the tablets (7 with a spoon and 13 with a hackneyed tablets), and 
9 assumed the oral suspension (Teglutik®, available on the market 
since March 2013) (Figure 4).
Among the 20 patients crushing riluzole tablets, 17 mixed 
them with water (16 through PEG, 1 to swallow), 1 mixed with 
tea, 1 with fruit, and 1 with a thickening solution.
The use of riluzole did not impact on survival either in 
dysphagic or in non-dysphagic patients (Gehan’s Wilcoxon 
test = 0.07; p = 0.93). In dysphagic patients, no difference in the 
time of death was observed between patients with bulbar and 
spinal onset (Gehan’s: Wilcoxon test = −1.23; p = 0.21).
Forty-eight percent of patients untreated with riluzole died, 
compared to 45% of those treated with whole tablets, 35% with 
crushed riluzole, and 22% with riluzole oral suspension. A 
significant difference in terms of mortality was found between 
patients untreated with riluzole and those treated with riluzole 
oral suspension (p < 0.05).
DiscUssiOn
In this study, we evaluated the clinical features associated with 
dysphagia in ALS patients and their impact on riluzole and food 
management.
FigUre 4 | administration of riluzole in amyotrophic lateral sclerosis (als) patients according to dysphagia.
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Our data are consistent with the literature: at the beginning of 
the disease, dysphagia was prevalent in patients with bulbar onset, 
and the duration of the disease affected mostly the frequency of 
dysphagia in spinal patients (21). Swallowing problems are often 
underestimated in ALS patients due to the progressive adaptation 
to slow deterioration of bulbar function, and the patient does not 
always recognize the disorder, leading to serious consequences 
and decreased survival. Dysphagia needs to be treated early and 
regularly to prevent complications, particularly in patients who 
do not initially perceive the disorder. This ensures adequate 
therapy through prevention of food aspiration and support of oral 
alimentation (via compensatory postures and dietary modifica-
tions), postponing PEG (22, 23). In the present study, 8% of spinal 
patients presenting with signs of dysphagia by FEES did not 
report the disorder as symptomatic. These findings emphasize 
the importance of performing a periodic objective swallowing 
evaluation in all ALS patients. Strategies to prevent malnutrition 
have a positive impact also on survival and quality of life (24, 25).
Recently, an important role has also been attributed to laryn-
geal sensitivity in the assessment of neurogenic oropharyngeal 
dysphagia (26). Laryngeal sensitivity is crucial for maintaining 
safe swallowing, thus avoiding silent aspiration. Until now, 
pharyngo-laryngeal sensitivity has received limited attention in 
patients with ALS, mainly because of the belief that ALS spares 
sensory function (27). In our study, FEES and PAS were able to 
objectively assess changes in the swallowing function over time, 
and this was particularly relevant in spinal patients, where the 
dysphagia may not even be recognized.
In patients with silent dysphagia, early detection is critical 
to avoid complications such as pneumonia. The management 
of oropharyngeal secretion and the efficacy of cleaning mecha-
nisms, such as coughing and throat clearing, can be assessed 
simply and directly by FEES (28). Moreover, it can be performed 
at the bedside, thus facilitating the examination of severely 
motor-impaired, bedridden, or uncooperative patients. The AAN 
practice parameters and European ALS Consortium suggests that 
nutrition education and management is the standard of care and 
recommends regular nutrition evaluation every 3  months in 
ALS patients (29). Treatment of dysphagia is based on swallow-
ing techniques, which improve the patient swallowing abilities 
thus reducing aspiration risks, and on diet change to adapt the 
consistency of foods and liquids to the patient specific impair-
ment (30). The multidisciplinary approach has improved the 
overall care of ALS patients. Nonetheless, otolaryngologists are 
often not included in ALS management until a tracheostomy is 
considered. In our series, 44% of dysphagic patients, above all 
dysphagic patients with spinal onset, refused requested thicken-
ers or PEG, and 25% of them had an impaired LAR. Paradoxically, 
we noted that patients who accepted thickening agents worsened 
more frequently compared to patients who refused them (67 vs. 
47%). An accurate analysis of data, however, showed that non-
compliant patients had a low level of disability and a better lung 
capacity. This suggests that any person who considers himself 
really ill makes everything possible to survive.
Seventy percent of patients who used PEG survived, and these 
data confirm that early recognition of dysphagia and of different 
grades of aspiration into the airways allows to identify patients 
who need PEG early on (29, 31, 32).
According to the literature, patients who were not treated with 
riluzole died more frequently compared to those receiving the 
drug, even if a significant difference was noted only for patients 
treated with oral suspension of riluzole (33). Since swallowing a 
pill is particularly problematic in these patients, the riluzole tablet 
is often crushed and dispensed with food. Both practices are not 
in line with riluzole label instruction, and no data are available 
about the efficacy and safety of crushed riluzole tablets. It is also 
important to remember that riluzole has anesthetic effects, as it 
partially blocks sodium channels, and it is usually administered 
in coated tablets to avoid oral paresthesia (34, 35). Considering 
the possible larynx sensory deficit in dysphagic ALS patients, the 
practice of crushing riluzole tablets could impair the swallow-
ing ability, therefore increasing the risk of aspiration. Moreover, 
7Onesti et al. Dysphagia in ALS
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this potential anesthetic effect could be prolonged if riluzole is 
dispersed in food, given the long time required by ALS patients to 
finish a meal. A comparative study between whole, crushed, and 
oral suspension of riluzole on a large number of ALS patients may 
help to understand the possible conditioning effect of different 
absorption of riluzole. Actually, the oral suspension of riluzole 
allows patients who suffer from dysphagia to receive the only 
approved ALS treatment in a way that does not alter the drug 
and is in line with the riluzole dosing instructions. Moreover, 
the viscosity of riluzole oral suspension is 300–700 cP (European 
Teglutik Patent No. 2405890B1), therefore similar to nectar and 
honey, allowing to minimize the risk of aspiration.
In conclusion, dysphagia is a very common symptom in 
ALS patients. The disease duration influences the occurrence 
of dysphagia especially in patients with spinal onset, appearing 
instead very early in patients with bulbar onset. Patients adapt 
food consistency according to the worsening of dysphagia, and 
they also alter riluzole tablet to swallow the drug. The pureed 
diets and PEG prescription increased over time, even if a high 
percentage of patients refused requested thickeners or PEG, 
despite LAR impairment. The oral suspension of riluzole would 
allow the safe administration of the drug in ALS patients with 
dysphagia without the need to crush the tablet or disperse 
it in food, practices that are inconsistent with their safe and 
effective use. An early and periodic nutrition assessment and 
therapeutic intervention is necessary to adequately modify the 
consistency of the diet and the proper use of thickening agents 
or PEG.
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